PTC Therapeutics, Inc. Restructuring Charges
PTC Therapeutics, Inc. (PTCT) reported Restructuring Charges of $22.60 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-10-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2023-10-26
- PTC Therapeutics, Inc. restructuring charges for the quarter ending 2023-09-30 was $22.60M.
- PTC Therapeutics, Inc. restructuring charges for the quarter ending 2023-06-30 was $8.00M.
- PTC Therapeutics, Inc. restructuring charges for the quarter ending 2016-03-31 was $1.90M.
- PTC Therapeutics, Inc. restructuring charges for fiscal 2017 was $0.00.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2023-09-30 | $22.60M 10-Q · filed 2023-10-26 | $30.60M derived: sum of 2 quarters · filed 2023-10-26 | $30.60M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $8.00M 10-Q · filed 2023-08-03 | $8.00M 10-Q · filed 2023-08-03 | ||
| 2017-12-31 | $0.00 10-K · filed 2018-03-06 | |||
| 2016-03-31 | $1.90M 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |